Written evidence submission from Global Institute for Novel Nicotine (GINN) to the Tobacco and Vapes Public Bill Committee

1. Executive Summary Safer nicotine products (SNPs), such as nicotine pouches, lozenges, gums, dissolvables and other reduced-risk nicotine alternatives, should not be regulated in the same manner as combustible smoking tobacco products and nicotine vaping products because they– • are smokeless and do not pose the same relative health risks; • readily contribute to a…

Regulatory Framework for Novel Nicotine Products: Broughton Life Sciences Recommendations

As the global conversation on tobacco harm reduction evolves, regulatory frameworks for novel nicotine products are under scrutiny. Broughton Life Sciences Ltd., a leading consultancy in life sciences, recently submitted comprehensive recommendations to the UK Parliament, offering a roadmap for establishing safety, quality, and compliance standards for nicotine pouches and other reduced-risk alternatives. Key Recommendations…